A self-assembly and stimuli-responsive fusion gelonin delivery system for tumor treatment
- Liu, Quan; Zhang, Lu; Ji, Xiuru; Shin, Meong Cheol; Xie, Shuping; Pan, Baoyan; Yu, Fei; Zhao, Jingwen; Yang, Victor C.
- Issue Date
- ELSEVIER SCIENCE INC
- Gelonin; Magnetic-nanoparticles; His-tagged fusion protein; Low-molecular-weight protamine; MMP-2; Tumor treatment
- JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY, v.89, pp.409 - 415
- Journal Title
- JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY
- Start Page
- End Page
- Ribosome-inactivating proteins (Rips) are potent protein toxins for cancer therapy, and they have strong ability to inhibit protein synthesis and induce cell death via inactivation of ribosomes in eukaryotic cells. However, the delivery of RIPs has been a challenging task due to their large molecular weight and lack of targeting property. Low molecular weight protamine (LMWP), a transmembrane peptide, has been proved to effectively promote transmembrane transportation, whereas the enzyme-activatable system can enhance the specificity by enhancing the tumor drug concentration through enzymatic reaction. We herein constructed a self-assembly and stimuli-responsive fusion gelonin delivery system. Gelonin, a typical RIP protein, was assembled with nickel ferrite nanoparticles by self-assembling between hexahistidine tag (His-tagged) and nickel ions. Both in vitro and in vivo results indicated that the magnetic nanoparticle carriers and the applied linkers did not damage the pharmaceutical effect of gelonin, and the whole drug delivery system showed good biocompatibility, sensitive selectivity, and significantly enhanced cytotoxic activity. This in turn presented theranostic nanoparticles as efficient delivery vehicle for clinical use. (C) 2020 The Korean Society of Industrial and Engineering Chemistry. Published by Elsevier B.V. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
- 약학대학 > 약학과 > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.